ASX/Media Release

18/02/2020

Emerald Clinics Medical Director to present at UK-Government-backed cannabis conference

Highlights

- *Emerald Director Associate Professor Alistair Vickery will join fellow Director Professor Sir John Tooke to present at inaugural Centre of Medicinal Cannabis conference in London*
- *Presentations to focus on Emerald's use of real-world evidence to inform safe use of cannabis-based medicinal products*
- *Highlights growing importance of real-world evidence in the adoption of cannabis-based products in mainstream medicine*
- *UK's Food Standards Agency to require registration of all cannabinoid products by March 2021, increasing the need for high-quality, clinical evidence to support claims*

Perth, Australia; 18 February 2020: Emerald Clinics Limited (**ASX: EMD**)(**Emerald** or the **Company**), a company establishing and operating a network of clinics specialising in the creation of robust and ethically-sourced evidence to guide appropriate use of unregistered medicines, including cannabinoid treatments, is pleased to announce it has accepted an invitation to present at the Centre of Medicinal Cannabis' inaugural conference in London in April 2020.

Emerald Clinics' Medical Director Associate Professor Alistair Vickery will join Professor Sir John Tooke in presenting at the conference, being conducted in collaboration with the UK's National Institute for Health Research (NIHR) and National Institute for Health and Care Excellence (NICE). Professor Sir John Tooke has been previously announced as a keynote speaker by the conference organisers.

Associate Professor Vickery will present Emerald Clinics' experience evaluating "1000 patients for CBMPs (cannabinoid-based medicinal products) and how deep learning can support systematised RWE (real-world evidence)", while Professor Sir Tooke is a keynote speaker for the event and will present a lecture titled "How we best use evidence to judge the benefits and harms of medicines", drawing on a major report conducted by the UK Academy of Medical Sciences he chaired on the topic.

Emerald Clinics Managing Director and CEO Dr Michael Winlo said the Company was honoured to present at the inaugural conference as the Company prepares for its expansion into the UK.

"There is growing interest in the use of medicinal cannabis across the global health system and an invitation to present at an event of this significance demonstrates the global relevance of the work that Emerald Clinics is doing," he said.

"CBMPs are complex medicines and require rigorous clinical study to evaluate their quality, safety and efficacy. The robust and ethically sourced clinical evidence we are generating through our clinical service will deliver important insights for CBMPs as they move toward becoming a mainstream medicine.

"The UK is a quickly evolving market for medicinal cannabis and the UK Government has adopted an evidence-based approach to its regulation. We remain on track to commence operations there in the near future."

Emerald's directors will be joined by prominent UK health professionals speaking at the conference including Dr Keith Ridge, Chief Pharmaceutical Officer at NHS England, and Dr Paul Chrisp, Director of the Centre for

Guidelines, NICE.

Emerald Clinics' invitation to speak at the conference followed an announcement by UK's Food Standards Agency (FSA) last week (13 February 2020) that manufacturers of cannabinoid (CBD) products will be required to register their products by 31 March 2021 or risk being removed from shelves. This further highlight the growing requirement for the type high-quality, product specific, clinical evidence that Emerald Clinics is delivering to the sector.

Release authorised by:
Dr Michael Winlo, CEO and Managing Director

For further information:

Dr Michael Winlo
CEO
(08) 6559 2800
investors@emeraldclinics.com.au

Matt Wright
Media/investor relations
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About Emerald Clinics Limited
Emerald Clinics Limited (ACN 625 085 734) is an Australian incorporated company that operates a network of specialist medical clinics (Clinics) and uses purpose-built software and technology to gather high quality clinical data from informed and consenting patients.

Emerald is a clinical services and healthcare technology company focussed on the provision of care for patients clinically determined to have exhausted conventional therapies and who may be suitable for cannabinoid-based medicines. In addition, Emerald uses technology to capture clinical data that can be used to generate clinical evidence relating to the safety and efficacy of unregistered medicines.

Emerald has established four medical centres in Australia including one site each in West Leederville WA, Woolloomooloo NSW, Tintenbar NSW and Richmond VIC.

Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a results of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.